FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow

Blood

Volumn 126, Issue 12, 2015, Pages 1494-1502

  Zhu, Shu ^a,b   Travers, Richard J ^c   Morrissey, James H ^c   Diamond, Scott L ^a,b  

^a Department of Chemical and Biomolecular Engineering ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; COLLAGEN; FIBRIN; PLATELET DERIVED POLYPHOSPHATE; POLYPHOSPHATE; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; ANTIBODY; THROMBIN;

ARTICLE; BLOOD CLOT RETRACTION; BLOOD CLOTTING; CONTROLLED STUDY; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; LYSIS; PRIORITY JOURNAL; SHEAR RATE; SURFACE PROPERTY; THROMBOCYTE; THROMBOSIS; BLOOD CLOTTING TEST; CYTOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ANTIBODIES; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; COLLAGEN; FACTOR XIA; HUMANS; MOLECULAR TARGETED THERAPY; POLYPHOSPHATES; SIGNAL TRANSDUCTION; THROMBIN; THROMBOPLASTIN; THROMBOSIS;

EID: 84942865527     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-641472     Document Type: Article

References (46)

1. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002;325(7368): 828-831.
2. Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160(1):35-46.
3. McFadyen JD, Jackson SP. Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemost. 2013;110(5): 859-867.
4. Smith JK. Factor XI deficiency and its management. Haemophilia. 1996;2(3):128-136.
5. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113(4): 936-944.
6. Wang X, Smith PL, Hsu MY, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006; 4(9):1982-1988.
7. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3- induced injury of the carotid artery in the mouse. Thromb Haemost. 2002;87(4):774-776.
8. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281.
9. Gruber A, Hanson SR. Factor XI-dependence of surface- And tissue factor-initiated thrombus propagation in primates. Blood. 2003;102(3): 953-955.
10. Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102-2107.
11. Yamashita A, Nishihira K, Kitazawa T, et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost. 2006;4(7):1496-1501.
12. Leung PY, Hurst S, Berny-Lang MA, et al. Inhibition of factor XII-mediated activation of factor XI provides protection against experimental acute ischemic stroke in mice. Transl Stroke Res. 2012;3(3):381-389.
13. Matafonov A, Leung PY, Gailani AE, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood. 2014; 123(11):1739-1746.
14. Kuijpers MJ, van der Meijden PE, Feijge MA, et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol. 2014;34(8): 1674-1680.
15. van Montfoort ML, Kuijpers MJE, Knaup VL, et al. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2014; 34(8):1668-1673.
16. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6): 1143-1156.
17. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood. 2011;118(26):6963-6970.
18. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA. 2006;103(4): 903-908.
19. Choi SH, Smith SA, Morrissey JH. Polyphosphate accelerates factor V activation by factor XIa. Thromb Haemost. 2015;113(3):599-604.
20. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood. 2008;112(7): 2810-2816.
21. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Arïens RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood. 2010;115(19):3980-3988.
22. Smith SA, Choi SH, Collins JNR, Travers RJ, Cooley BC, Morrissey JH. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood. 2012; 120(26):5103-5110.
23. Gailani D. Future prospects for contact factors as therapeutic targets. Hematology Am Soc Hematol Educ Program. 2014;2014(1):52-59.
24. Colace TV, Muthard RW, Diamond SL. Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin. Arterioscler Thromb Vasc Biol. 2012;32(6):1466-1476.
25. Maloney SF, Brass LF, Diamond SL. P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. Integr Biol (Camb). 2010;2(4):183-192.
26. Fogelson AL, Hussain YH, Leiderman K. Blood clot formation under flow: The importance of factor XI depends strongly on platelet count. Biophys J. 2012;102(1):10-18.
27. Büller HR, Bethune C, Bhanot S, et al; FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3): 232-240.
28. Flaumenhaft R. Making (anti)sense of factor XI in thrombosis. N Engl J Med. 2015;372(3): 277-278.
29. Duarte JH. Anticoagulation therapy: Reducing factor XI with antisense oligonucleotides superior to endoxaparin for postoperative venous thromboembolism. Nat Rev Cardiol. 2015;12(2): 66.
30. Puy C, Tucker EI, Matafonov A, et al. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood. 2015;125(9): 1488-1496.
31. Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol. 1999;19(1):170-177.
32. Björkqvist J, Nickel KF, Stavrou E, Renné T. In vivo activation and functions of the protease factor XII. Thromb Haemost. 2014;112(5):868-875.
33. Zhu S, Diamond SL. Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay. Thromb Res. 2014;134(6): 1335-1343.
34. Kravtsov DV, Matafonov A, Tucker EI, et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood. 2009;114(2): 452-458.
35. Puy C, Tucker EI, Wong ZC, et al. Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. J Thromb Haemost. 2013; 11(7):1341-1352.
36. Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116(19): 3981-3989.
37. Welsh JD, Colace TV, Muthard RW, Stalker TJ, Brass LF, Diamond SL. Platelet-targeting sensor reveals thrombin gradients within blood clots forming in microfluidic assays and in mouse. J Thromb Haemost. 2012;10(11):2344-2353.
38. Neeves KB, Maloney SF, Fong KP, et al. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J Thromb Haemost. 2008;6(12): 2193-2201.
39. Duckers C, Simioni P, Spiezia L, et al. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood. 2010;115(4): 879-886.
40. Li R, Fries S, Li X, Grosser T, Diamond SL. Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin. Clin Chem. 2013;59(8): 1195-1204.
41. Colace TV, Fogarty PF, Panckeri KA, Li R, Diamond SL. Microfluidic assay of hemophilic blood clotting: distinct deficits in platelet and fibrin deposition at low factor levels. J Thromb Haemost. 2014;12(2):147-158.
42. Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood. 2010; 116(20):4353-4359.
43. Nickel KF, Spronk HM, Mutch NJ, Renné T. Timedependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood. 2013;122(23):3847-3849.
44. Faxälv L, Boknäs N, Ström JO, et al. Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII. Blood. 2013;122(23): 3818-3824.
45. Boknäs N, Faxälv L, Ström JO, et al. Response: platelets do not generate activated factor XII-how inappropriate experimental models have led to misleading conclusions. Blood. 2014;124(10): 1692-1694.
46. Lam WA, Chaudhuri O, Crow A, et al. Mechanics and contraction dynamics of single platelets and implications for clot stiffening. Nat Mater. 2011; 10(1):61-66.